Clinical Trials Logo

Cervical Cancer clinical trials

View clinical trials related to Cervical Cancer.

Filter by:

NCT ID: NCT06304610 Not yet recruiting - Cervical Cancer Clinical Trials

Hospital-based Validation of the New ELEVATE Screening Tool in Belgium and Ecuador

ELEVATE-Pilot
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

ELEVATE is a six-year project, conducted by an international research alliance led by Ghent University, aiming to develop a new test and approach for cervical cancer screening in hard-to-reach populations. In this final stage of the project, a hospital-based validation study is deployed in Belgium and Ecuador to clinically validate the new ELEVATE screening test based on self-samples and endocervical samples. The simultaneous detection of HPV DNA and the proteomic markers allows for the detection of those cervical HPV infections associated with progression towards cervical cancer. At each study site, 100 women between 30-65 years old, with a recent abnormal pap smear result will be recruited in the colposcopy waiting room. After registration and signing the informed consent form, each woman will be asked to fill out a short self-administered questionnaire for socio-demographic information. Each woman will provide a self-sample as well as an endocervical sample before the colposcopy examination. Both samples of all 200 women (i.e. participants from Belgium and Ecuador) will be tested with the new ELEVATE screening test, using 400 ELEVATE cartridges, as well as with standard tests. Besides analyzing all samples on the new ELEVATE screening test, the following standard tests will also be performed on all samples (at Ghent University - including the shipped samples of Ecuador): - AnyplexTM II HPV HR Detection (Segeene Inc., Korea): approved comparison test - ELISA protein detection: only available comparison test In order to generate HPV DNA results locally, that can be communicated to the participants in short time (versus waiting for AnyplexTM II HPV HR Detection test results after shipment to Belgium), in Ecuador the following additional standard test will be performed on the100 endocervical samples (before shipment to Belgium): • HPV DNA Mole Bioscience test Concordance between the test results of the ELEVATE screening test and standard lab tests on both type of samples will be defined, for HPV DNA as well as protein detection. Additionally, the sensitivity and specificity of the HPV DNA test and the protein test of the ELEVATE screening test will be defined, according to clinically relevant outcomes.

NCT ID: NCT06297811 Not yet recruiting - Breast Cancer Clinical Trials

Myeloprotection With Trilaciclib in Pan-cancer Population

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

The goal of this open-label randomized controlled study is to assess the myeloprotective effect of trilaciclib in pan-cancer population. The main questions it aims to answer are: - effect and safety of trilaciclib on myeloprotection in cancer patients receiving paclitaxel plus carboplatin chemotherapy - does trilaciclib 's myeloprotective efficacy in patients receiving the same chemotherapy regimen correlate with tumor type Participants will be randomized 2:1 to the treatment arm of trilaciclib in combination with a paclitaxel and carboplatin-based regimen and the control arm of a paclitaxel and carboplatin-based regimen for at least 6 cycles or until disease progression or intolerable toxicity. Patients in both groups could extend the chemotherapy cycle at the investigator 's discretion depending on the tumor type and in combination with anti-angiogenic/PD-X/anti-HER2 therapy.

NCT ID: NCT06293898 Recruiting - Ovarian Cancer Clinical Trials

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Start date: February 9, 2024
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

NCT ID: NCT06291311 Recruiting - Cervical Cancer Clinical Trials

Non-Invasive Plasma Treatment for Cervical Infections: Targeting High- and Low-Risk HPV Variants

Start date: December 27, 2023
Phase:
Study type: Observational

This is a prospective, single-center, observational proof-of-principle clinical trial at the Department of Women's Health of the University Hospital Tübingen.

NCT ID: NCT06289751 Not yet recruiting - Cervical Cancer Clinical Trials

Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

This study is an exploratory clinical trial to investigate the feasibility of neoadjuvant chemoimmunotherapy plus extrafascial hysterectomy and pelvic lymph node dissection in patients with stage IB2 (2018 FIGO) cervical cancer and to observe the response rate to treatment, adverse effects and complications, and to assess the survival rate of patients.

NCT ID: NCT06289062 Not yet recruiting - Cervical Cancer Clinical Trials

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

This multicenter, prospective clinical trial is designed to enroll PD-L1 expression-positive patients with stage IB1 cervical cancer who desire fertility preservation to undergo neoadjuvant chemotherapy in combination with a PD-1 inhibitor to evaluate the rate of complete pathologic remission, treatment-related adverse events, pregnancy rate, miscarriage rate, preterm birth rate, live birth rate, PFS and OS.

NCT ID: NCT06288373 Not yet recruiting - Cervical Cancer Clinical Trials

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Start date: March 1, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

It is a prospective, open-label, randomized, controlled phase II/III clinical trial in which patients with PD-L1-positive FIGO stage IB3, IIA2 and IIB(tumors >4 cm in diameter)will be enrolled and randomly divided into the neoadjuvant chemoimmunotherapy plus surgery group and the CCRT group.

NCT ID: NCT06288360 Not yet recruiting - Cervical Cancer Clinical Trials

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

This is a multicenter, prospective, single-arm, phase 2 clinical trial designed to evaluate the therapeutic efficacy of the NACI (neoadjuvant chemotherapy plus Camrelizumab) for PD-L1-negative locally advanced cervical cancer.

NCT ID: NCT06286462 Recruiting - Cervical Cancer Clinical Trials

Evaluation of the Cancer Tracking System (CATSystem)

CATSystem
Start date: February 5, 2024
Phase: N/A
Study type: Interventional

Cervical cancer contributes to significant preventable mortality in Kenya where less than 20% of women are screened. The Cancer Tracking System (CATSystem) is a web-based, algorithm generated tool to promote guideline adherent cervical cancer screening and retention through treatment. The goal of this project is to rigorously evaluate the efficacy, implementation, and cost-effectiveness of the CATSystem to improve rates of screening, treatment, referral, and follow-up care in a matched, cluster randomized controlled trial in 10 Kenyan government hospitals (5 intervention, 5 standard of care).

NCT ID: NCT06284031 Recruiting - Cervical Cancer Clinical Trials

Cervical Cancer Brachytherapy With Interstitial Needles in 3 Fractions

Start date: June 26, 2023
Phase: N/A
Study type: Interventional

Aim To determine the feasibility and safety of 3 fractions of high dose rate (HDR) brachytherapy with interstitial needles for cervical cancer in the outpatient setting Primary objective To determine the clinical outcome (2-yr local control rate, loco-regional control rate, progression free survival and overall survival) Secondary objective To determine the long-term toxicities of this regimen based on CTCAE v5